Search Site

Trends banner

TomTom cuts 300 jobs

The firm said it was realigning its organization as it embraces AI.

Aldar nets $953m in sales at Fahid

Aldar said 42 percent of the buyers are under the age of 45.

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

Equinor signs $27 bn gas deal

The 10-year contract was signed with Centrica.

ADNOC Drilling secures $1.15bn contract

The contract for two jack-up rigs begins in the second quarter.

Glaxo buys Bellus for US$2bn

A Bellus treatment under clinical development, Camlipixant, is expected to receive regulatory approvals and launch in 2026. (AFP)
  • GSK has agreed to buy Quebec-based biopharmaceutical Bellus Health Inc. for $14.75 per share, the British drugmaker said in a statement.
  • Chronic cough is defined as a persistent cough that lasts more than eight weeks and affects an estimated 28 million people worldwide.

LONDON, UK – British drugmaker GlaxoSmithKline on Tuesday announced the purchase of Canadian chronic cough treatment specialist Bellus for US$2 billion.

It comes after GSK, led by chief executive Emma Walmsley, demerged its consumer healthcare unit Haleon last year, leaving the group to focus on drugs.

GSK has agreed to buy Quebec-based biopharmaceutical Bellus Health Inc. for $14.75 per share, it said in a statement.

Chronic cough, defined as a persistent cough that lasts more than eight weeks, affects an estimated 28 million people worldwide.

While there are no approved medicines in the European Union or United States, a Bellus treatment under clinical development, Camlipixant, is expected to receive regulatory approvals and launch in 2026.

“Patients suffering from severe forms of refractory chronic cough can experience over 900 coughs daily, resulting in quality-of-life issues,” GSK’s chief commercial officer Luke Miels said in the statement.

“Camlipixant… has the potential to be a best-in-class treatment with significant sales potential,” he added.